Article: Medtronic Starts U.S. and International Trials of Endeavor(R) Resolute Drug-Eluting Coronary Stent.

New Research Studies Will Enroll More Than 3,500 Patients at 200-Plus Investigational Sites Worldwide

MINNEAPOLIS -- Consistent with its commitment to advancing the treatment of cardiovascular disease through innovative product design and rigorous clinical research, Medtronic, Inc. (NYSE: MDT), announced today the start of two new trials of the Endeavor([R]) Resolute drug-eluting stent (DES), the company's innovative complement to the Endeavor drug-eluting stent, which was approved by the U.S. Food and Drug Administration (FDA) in February 2008.

Clinical research teams led by interventional cardiologists Dr. James Carr at East Texas Medical Center in the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!